Editorial & perspective

☞ Academic Editorial

1. Natural Products and Gut Microbiome Metabolism in Hepatobiliary Gastrointestinal Diseases, 2025; 20(6), Natural Product Communications; https://doi.org/10.1177/1934578X251356015

2. Advances in Pathogenesis and Therapeutics of Hepatobiliary Diseases II,Biomedicines 2025, 13(4), 904; https://doi.org/10.3390/biomedicines13040904

3. The Role of Commensal Microbiota in Drug Metabolism: Friend or Foe? Frontiers in Microbiology 2024,15, 1364747; https://doi.org/10.3389/fmicb.2024.1364747

4. Advances in Pathogenesis and Therapeutics of Hepatobiliary Diseases. Biomedicines 2023, 11(4), 1140; https://doi.org/10.3390/biomedicines11041140

5. Complementary and Alternative Medicine for Diseases and Disorders in Digestive Tract: Basic to Clinics. WILEY, Evidence-Based Complementary and Alternative Medicine, 2013, 565279, http://dx.doi.org/10.1155/2013/565279

6. Medicinal Herbs and Their Active Compounds for Fatty Liver Diseases. WILEY, Evidence-Based Complementary and Alternative Medicine, 2017, 3612478, https://doi.org/10.1155/2017/3612478

☞ Academic Perspective

1. Therapeutic Potential of Prevotella spp. in Metabolic Disorders: Integrating Herbal Medicine and Gut Microbiome, 2025/09, Traditional Medicine Research, acceptance